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Objectives: Contemporary cardioprotective strategies to prevent perioperative
ischemia-reperfusion injury have focused on the L-arginine nitric oxide pathway.
Tetrahydrobiopterin is an absolute cofactor required for the enzyme nitric oxide
synthase and is thus a critical determinant of nitric oxide production. We hypoth-
esized that ischemia-reperfusion results in diminished levels of tetrahydrobiopterin,
which might represent a key cellular defect underlying endothelial and myocyte
dysfunction after ischemia-reperfusion. To this aim, we examined the effects of
tetrahydrobiopterin supplementation in (1) an in vivo experimental model of global
ischemia-reperfusion and (2) an in vitro human ventricular heart cell model of
simulated ischemia-reperfusion. Measures of endothelial function, oxidant produc-
tion, cell survival, and cardiac function were used to assess outcome.
Methods: In study 1 Wistar rats were divided into one of 2 groups (n  10 per
group). One group received tetrahydrobiopterin (25 mg  kg1  d1 for 7 days), and
the other group served as the control group. Hearts were subjected to 30 minutes of
ischemia followed by 30 minutes of reperfusion, and left ventricular developed
pressure, left ventricular systolic pressure, and left ventricular end-diastolic pressure
were determined by using the modified Langendorff technique. In study 2 we
quantitated myocardial malondialdehyde, a marker of lipid peroxidation, in ventric-
ular tissues from both groups of animals using butanol phase extraction and
spectrophotometric analysis. In study 3 coronary vascular responses were deter-
mined in vascular segments of the left coronary artery in both groups of animals
after ischemia-reperfusion. Endothelium-dependent and endothelium-independent
vasodilatation to acetylcholine and sodium nitroprusside, respectively, were com-
pared between groups. In study 4, using a human ventricular heart cell model of
simulated ischemia-reperfusion, we studied the effects of tetrahydrobiopterin (20
mol/L) on cellular injury (as assessed by means of trypan blue uptake).
Results: After ischemia-reperfusion, myocardial dysfunction was evidenced by a de-
crease in left ventricular developed pressure and an increase in left ventricular end-
diastolic pressure (P  .01 compared with baseline). Hearts from tetrahydrobiopterin-
treated rats exhibited protection against ischemia-reperfusion injury (left ventricular
developed pressure: 74  4 vs control 42  8 mm Hg, P  .01; left ventricular
end-diastolic pressure: 12  3 vs 34  7 mm Hg, P  .01). Furthermore,
tetrahydrobiopterin treatment attenuated the rise in malondialdehyde levels after
ischemia-reperfusion (P  .01). After reperfusion, coronary endothelial function to
acetylcholine was attenuated (P .003 vs sham-treated mice), whereas responses to
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sodium nitroprusside remained unchanged. Tetrahydrobiopterin-treated rats exhib-
ited an improvement in acetylcholine-mediated vasorelaxation (P  .01 vs ischemia-
reperfusion group). Cellular injury, as assessed by means of trypan blue uptake, was
higher in human ventricular heart cells subjected to simulated ischemia-reperfusion;
this effect was prevented with tetrahydrobiopterin treatment (P  .001).
Conclusions: Supplemental tetrahydrobiopterin provides a novel cardioprotective
effect on left ventricular function, endothelial-vascular reactivity, oxidative damage,
and cardiomyocyte injury after ischemia-reperfusion injury and might represent an
important cellular target for future operative myocardial protection strategies.
One of the most common and predictableforms of ischemia-reperfusion (I/R) in-jury occurs during cardiac operations,when the heart is arrested for surgicalintervention and subsequently reperfusedby removal of the aortic crossclamp. De-
vising pharmacologic strategies to counter perioperative I/R
injury might serve to restore functional integrity during
cardioplegic arrest. Contemporary cardioprotective strate-
gies to prevent I/R injury have focused on the L-arginine–
nitric oxide (NO) pathway. Tetrahydrobiopterin (BH4) is an
essential cofactor required for nitric oxide synthase (NOS),
and hence NO production is critically dependent on the
presence of adequate amounts of BH4.1-4 Diminished levels
of BH4 might lead to an uncoupling of NOS, with the
resultant production of reactive oxygen species instead of
NO. The beneficial effects of BH4 supplementation have
been recently confirmed in a variety of cardiovascular dis-
ease states.1-3,5
In the present study we hypothesized that I/R injury
results in diminished bioavailability of BH4, which might
lead to endothelial and myocyte dysfunction. To this aim,
we examined the effects of BH4 treatment on cardiac dys-
function, impaired endothelium-dependent vasodilatation,
and lipid peroxidation in a model of global I/R. To examine
whether BH4 exerts direct cardioprotective effects (indepen-
dent of other cell types), we studied the effects of this
cofactor on cellular injury in a human ventricular cardio-
myocyte model of simulated I/R. We herein report, for the
first time, novel cardioprotective effects of BH4 on the
aforementioned pathways, which suggest that BH4 might




Male Wistar rats (200-250 g) were divided into one of 2 groups
(n  10 per group). Experiments were performed in accordance
with the Canadian Animal Care Guidelines. The first group of rats
was treated with BH4 (25 mg  kg1  d1 administered intrave-
nously) for 7 days, and the second group of rats received saline
injections. Similar doses have been used in an experimental model
of porcine lung transplantation.3 After treatment, hearts were ex-
cised for isolated perfusion study by using the modified Langen-
dorff technique.
Isolated Perfused Heart Study
All rats were anesthetized with sodium pentobarbital (60 mg/kg
administered intraperitoneally), and the hearts were removed and
placed in ice-cold Krebs buffer with the following composition:
120 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L KH2PO4, 1.2
mmol/L MgSO4, 1.25 mmol/L CaCl2, 25 mmol/L NaHCO3, and
11 mmol/L glucose (pH 7.4). The hearts were then transferred to
the isolated perfusion apparatus and perfused in a retrograde
fashion through the aorta with oxygenated (95% O2 and 5% CO2)
Krebs buffer maintained at 37°C. The hearts were electrically
stimulated at a rate of 300 beats/min and perfused at a constant
flow rate of 10 mL/min. A water-filled latex balloon was inserted
into the left ventricle through the left atrium and connected to a
pressure transducer (Gould Satham) for the measurement of left
ventricular end-diastolic pressure (LVEDP), left ventricular sys-
tolic pressure, and left ventricular developed pressure (LVDP; ie,
left ventricular systolic pressure minus LVEDP). LVEDP during
the phase of equilibration was set between 5 and 8 mm Hg.
Four hearts from the saline-treated group were continuously
perfused with Krebs buffer for 90 minutes and served as the sham
control group. Hearts from the other rats were subjected to 30
minutes of global ischemia followed by 30 minutes of reperfusion.
The Krebs buffer was supplemented with BH4 (20 mol/L) during
the assessment of the treated group. After completion of the
experiment, the hearts were frozen in liquid nitrogen for the
assessment of malondialdehyde (MDA), a marker of lipid peroxi-
dation, as described below.
Determination of MDA Levels in Myocardium
MDA levels in the myocardium were measured in duplicate by
using a modification of the method of Ohkawa and associates,6 as
described by Chen and colleagues.7 Ventricular tissue was dis-
sected and homogenized. The assay mixture consisted of 0.1 mL of
the tissue homogenate, 0.4 mL of 0.9% NaCl, 0.5 mL of 3%
sodium dodecylsulfate, and 3 mL of thiobarbituric acid and acetic
acid and was heated for 75 minutes at 95°C. Thereafter, 1 mL of
cold 0.9% NaCl was added to the mixture, which was cooled and
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extracted with 5 mL of n-butanol. After centrifugation at 3000 rpm
for 15 minutes, the butanol phase was assayed spectrophotometri-
cally at 532 nm. Tetrahmethoxypropane (in amounts of 0, 0.1, 0.2,
0.4, 0.8, and 1.0 nmol) served as the external standard. MDA
levels in myocardium were expressed as micromoles per gram of
tissue.7
Endothelial Function Assessment
In a separate experiment we examined the effects of BH4 treatment
on endothelium-dependent and endothelium-independent vascular
relaxation after global I/R injury. Briefly, after I/R, the left coro-
nary artery was dissected under a microscope, and vascular seg-
ments (1-2 mm in length) were used for the assessment of in vitro
vascular function by using a small-vessel myograph for isometric
tension recording. Care was taken during dissection and mounting
to avoid damage to the endothelium. Briefly, after stabilization, the
vessels were stimulated according to the following protocol: (1)
cumulative dose-response curve (DRC) to phenylephrine (109-
105 mol/L); (2) DRC to acetylcholine (109-105 mol/L) in
rings precontracted with the effective dose causing 75% maximum
contraction (ED75) of phenylephrine; and (3) DRC to sodium
nitroprusside (SNP; 1011-106 mol/L) in rings precontracted
with the ED75 of phenylephrine. The percentage of maximum
relaxation was compared between groups.
Human Heart Cell Model of I/R
Our method of culturing heart cells from human ventricular biopsy
specimens has been previously described in detail.8,9 In brief, 5- to
20-mg biopsy specimens were obtained from the right ventricular
outflow tract of patients undergoing elective operations for tetral-
ogy of Fallot. The average age of the patients ranged from 4 to 14
years. After digestion with trypsin (0.2%) and collagenase (0.1%),
the separated cells were seeded onto cell-culture dishes and cul-
tured at 37°C and 5% CO2 in Iscove’s modified Dulbecco’s
medium with 10% fetal bovine serum, 100 U/mL penicillin, 100
g/mL streptomycin, and 0.1 mmol/L -mercapthoethanol. Puri-
fication was achieved by using a dilution cloning technique. En-
zymatically isolated cells were seeded at a low density to enable
morphologic identification of individual cardiomyocytes and sep-
aration from contaminating cell types. Single cardiomyocyte col-
onies were then transferred to a separate culture dish. The use of
cardiomyocytes facilitates examining the contribution of I/R inde-
pendent of other cell types, such as endothelial cells or fibroblasts.
Our technique of simulated I/R has also been described in detail
previously.8,9 In brief, after 30 minutes of stabilization in 10 mL of
normoxic phosphate-buffered saline (PBS), ischemia was simu-
lated by exposing the cells to a low volume (1.6 mL) of anoxic
PBS at 37°C for 90 minutes. During this period, the cells were
placed in an airtight Plexiglas chamber, which was continuously
flushed with 100% nitrogen to maintain anoxic conditions. Isch-
emia was followed by a reperfusion period in which the cells were
exposed to 10 mL of normoxic PBS at 37°C for 30 minutes. Both
low-volume and anoxic conditions were used to mimic ischemia.
The volume of anoxic perfusate used (1.6 mL) was the minimum
volume required to coat the cellular monolayer for the prevention
of cellular dehydration during the ischemic period. To verify the
presence of anoxia, we placed 2 mL of anoxic PBS in a center dish
within the sealed chamber and tested at the termination of each
ischemic period to ensure a PO2 of 0 mm Hg. Anoxic PBS was
prepared by bubbling with 5% CO2 and 95% nitrogen that had first
been passed through an oxygen trap (1% wt/vol NaHSO3 in
deionized water). The solution (monitored with a blood gas ana-
lyzer) was degassed until a PO2 of 0 mm Hg and a PCO2 of less than
10 mm Hg were achieved. A pH of 7.4  0.05 and an osmolality
of 290 20 mOsm/L were ensured before use. For the assessment
of cellular injury, cells were stained with trypan blue at the end of
the reperfusion period (after 150 minutes of incubation for the
nonischemic groups). Injured cells were unable to exclude the
large-molecular-weight dye and stained blue. The above protocol
was repeated in the presence of BH4 (20 mol/L) added before
reperfusion. A single blinded observer performed cell counts.
Statistical Analysis
Data are presented as means  SEM. Data were compared by
using a 2-way analysis of variance followed by the Newman-Keuls
test for post hoc comparisons.
Figure 1. LVDP after 30 minutes of global ischemia and 30 minutes of reperfusion. I/R caused marked cardiac
dysfunction. BH4 supplementation improved functional recovery after I/R. *P  .01 versus I/R.
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The baseline values of LVDP and LVEDP did not differ
between the groups at baseline (P  .2). The sham group
exhibited no changes in cardiac function during the 90-
minute perfusion period (P  .2). After 30 minutes of
global ischemia and 30 minutes of reperfusion, the hearts in
the untreated groups exhibited cardiac dysfunction, as evi-
denced by a decrease in LVDP and an increase in LVEDP
(Figures 1 and 2, P  .01). Strikingly, treatment of the rats
with BH4 attenuated I/R-induced myocardial dysfunction,
as evidenced by preservation in LVDP and a minimal in-
crease in LVEDP (Figures 1 and 2, P  .004).
Myocardial MDA levels
MDA levels were measured in both groups of rats after I/R
as an index of lipid peroxidation.7,10,11 After I/R, MDA
levels increased in the myocardium (Figure 3); this effect
was attenuated with BH4 treatment (P  .01).
Coronary Endothelial Function
Coronary vascular reactivity to endothelium-dependent
(acetylcholine) and endothelium-independent (SNP) vaso-
dilatation was assessed in the left anterior descending artery
after I/R. Global I/R resulted in endothelial dysfunction, as
evidenced by diminished acetylcholine-mediated vasorelax-
ation (P  .003). Endothelium-independent responses to
SNP remained unchanged after I/R (not shown). Impor-
tantly, treatment with BH4 improved acetylcholine re-
sponses, indicating a preservation of endothelial function
after I/R (Figure 4, P  .001).
Cardiomyocyte Cell Injury
Figure 5 depicts the effects of simulated I/R on cellular
injury (as assessed by trypan blue exclusion) in the presence
or absence of BH4 (20 mol/L) added during reperfusion.
I/R resulted in marked cardiomyocyte cell injury when
compared with that seen in the nonischemic control group
(P  .001). This response was completely prevented with
BH4 treatment (P  .001).
Discussion
Key Observations
The following observations have been made in this study:
(1) supplementation with the essential NOS cofactor BH4
improves functional recovery after global I/R; (2) I/R-
induced increases in myocardial MDA levels, an index of
lipid peroxidation, are attenuated by BH4; (3) BH4 treatment
restores impaired endothelial function in epicardial coro-
nary arteries after global I/R; and (4) acute BH4 incubation
exerts direct cardioprotective effects in human cardiomyo-
cytes subjected to simulated I/R. These data underscore the
importance of BH4 as a mediator of I/R injury and suggest
that this cofactor might exert myocardial protection through
Figure 2. LVEDP after 30 minutes of global ischemia and 30 minutes of reperfusion. I/R caused an increase in LVEDP.
BH4 supplementation improved functional recovery after I/R, as evidenced by a significantly lower increase in
LVEDP after I/R. *P  .01 versus I/R.
Figure 3. Myocardial MDA levels in the myocardium. In response
to I/R, there was a significant increase in MDA levels. Treatment
with BH4 attenuated MDA levels, a marker of lipid peroxidation.
*P  .01 versus control.
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prevention of endothelial dysfunction, lipid peroxidation,
and direct cardiomyocyte injury.
BH4: An Emerging Cardiovascular Target
In the endothelial cell NO is synthesized from L-arginine by
NO synthase (endothelial NOS or NOS III). BH4 is an
essential cofactor required for the activation of NOS and the
production of NO. Mechanistically, BH4 functions as a
reducing cofactor, transferring electrons to the enzyme-
bound L-arginine.1,12 Furthermore, it promotes stabilization
of the dimeric (active) form of NOS and also increases the
affinity of NOS for L-arginine. Additionally, in the presence
of low levels of BH4, NOS functions as a reduced nicotin-
amide adenine dinucleotide phosphate oxidase, resulting in
the production of oxygen-derived free radicals instead of
NO.1 Thus decreased levels of BH4 might lead to dimin-
ished NO production, enhanced NO breakdown, or both.
Decreased availability of BH4 has now been implicated as a
pathogenic factor causing endothelial dysfunction in a va-
riety of cardiovascular disease states. Likewise, acute and
chronic supplementation with BH4 has been demonstrated
to improve endothelium-dependent vasomotion clinically
and experimentally.1-3,5
Accumulating evidence suggests that modulation of the
L-arginine-NO pathway might exert cardioprotective effects
after I/R.13-15 Previous studies, including work from our
group,15 have demonstrated that L-arginine supplementation
exerts cardioprotective effects by means of increasing NO
production. Given the importance of BH4 in the regulation
of NOS, we set out to determine whether exogenous sup-
plementation of this cofactor would enhance functional
recovery and endothelial function in an experimental model
of global I/R. In addition, we tested the hypothesis that BH4
exerts direct cardioprotective effects (independent of endo-
thelial cells) in human ventricular cardiomyocytes subjected
to I/R.
Potential Mechanisms of BH4 Cardioprotection
I/R injury incites an acute inflammatory response that af-
fects the structure, function, and metabolism of the endo-
thelium and cardiomyocyte. The cellular element of the
microvasculature that appears to be most affected by I/R is
the endothelium. Ischemia is known to alter the membrane
potential, increase intracellular volume, and impair cy-
toskeletal organization of the endothelial cell.16 From a
functional standpoint, endothelium-dependent vasodilata-
tion is impaired,17-19 whereas the responses to endothelium-
Figure 4. Coronary endothelial function assessment. Vascular responses to the endothelium-dependent vasodilator
acetylcholine (Ach) were studied in segments of left coronary arteries precontracted with the ED75 of phenyleph-
rine. I/R resulted in endothelial dysfunction, and this response was prevented with BH4 treatment. *P .003 versus
sham and I/R  BH4 groups.
Figure 5. Cell injury, as assessed by means of trypan blue uptake,
in human ventricular heart cells subjected to simulated I/R. BH4,
when used as a prereperfusion strategy, completely prevented
I/R-induced cardiomyocyte injury. *P 0.001 versus nonischemic
control.
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derived contracting factors are exaggerated after I/R. Endo-
thelial dysfunction occurs rapidly during reperfusion and
sets the stage for leukocyte-endothelial cell interaction, an
important factor in the pathophysiology of I/R injury. The
generation of oxygen-derived free radicals is also an impor-
tant mechanism of I/R injury. Dysfunctional endothelium
and activated neutrophils are important sources of oxidants,
such as superoxide anion. Under normal conditions, the flux
Figure 6. Top, BH4 is a critical cofactor for endothelial NOS (eNOS). In the presence of adequate amounts of BH4,
NOS is coupled and produces mainly NO and small amounts of superoxide. Bottom, I/R might directly impair BH4
bioavailability. This results in an uncoupling of NOS, with a resultant increase in superoxide versus NO production.
BH4 supplementation might represent a novel cellular target for future operative myocardial protective strategies.
L-arg, L-arginine; ec, endothelial cell; vsmc, vascular smooth muscle cell.
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of NO greatly exceeds the rate of superoxide production.
This allows NO to effectively scavenge the low intracellular
levels of superoxide, repel neutrophil adhesion, and exert
endothelium-dependent vasodilatation. However, within
minutes of reperfusion, the balance between NO and super-
oxide generation is altered in favor of the latter. In addition
to enhanced potential for oxygen radical generation, post-
ischemic hearts might exhibit a decrease in the tissue con-
centration of intracellular oxidant scavengers, which might
further predispose to myocardial damage.
The beneficial effects of BH4 observed in the present
studies likely result from the production of NO, a correction
of reperfusion-induced changes in superoxide-NO balance,
or both (Figure 6). Both decreased NO production and
increased superoxide anion release are well-known inhibi-
tors of endothelial function. Therefore the improvements in
endothelial function might have resulted from either one of
these mechanisms or a collective effect on both pathways.
In an experimental model of global I/R, we present evidence
to suggest that BH4 might augment functional recovery after
I/R by preventing coronary endothelial dysfunction and
decreasing MDA, a product of lipid peroxidation and index
of tissue injury. However, data from our human heart cell
model suggest that BH4 might exert direct cardiomyocyte
protection independent of the presence of endothelial cells,
neutrophils, platelets, or fibroblasts. The ability of BH4 to
exert direct cardioprotective effects in the absence of endo-
thelial cells might appear atypical at first; however, we have
recently observed similar direct cardioprotective effects of
L-arginine and NO donors in this model of simulated I/R.15
In addition, evidence from our research group suggests that
NO might attenuate cardiomyocyte injury by opening of
KATP channels in a cyclic guanosine monophosphate–
dependent fashion. Hence it is possible that through improv-
ing NO production-balance, BH4 exerts cardioprotective
effects similar to those noted previously with L-arginine.
The mechanism of injury in the Langendorff and in vitro
cell-culture preparation might be more weighted toward
oxidant injury, and hence BH4 should be tested in an in vivo
model in which both mechanisms and their interactions are
engaged.
An important question that merits some discussion re-
lates to the potential clinical applicability of L-arginine
versus BH4 as therapeutic strategies for modulating NO-
mediated cardioprotection. Although low-dose L-arginine
and BH4 might function in a very similar fashion in terms of
their cardioprotective effects, the dose-response relationship
for L-arginine is narrow; higher doses of L-arginine might
actually exaggerate cardiomyocyte injury through excessive
NO production (Weisel RD, unpublished observations). We
believe that one of the primary abnormalities after I/R is a
decrease in BH4 levels. Several biochemical studies have
demonstrated that activation of NOS in the presence of
suboptimal BH4 concentrations results in uncoupling of
oxygen reduction and arginine oxidation, with the resultant
formation of superoxide anion and hydrogen perox-
ide.12,20-22 Hence NOS might become a source of oxygen-
derived free radicals in the face of low levels of this cofac-
tor, and there is strong evidence to support this conclusion
in vitro.12,20-24 Treatment with BH4 might therefore serve to
restore the NO-superoxide anion balance without the dele-
terious effects of excess NO production observed with high-
dose L-arginine administration. BH4 has very low toxicity
and can be administered intravenously in high doses.25
Critique of the Human Ventricular Heart Cell Model
A critique of the model of simulated I/R is provided. The
heart cells used in these studies have been extensively
evaluated in previous reports. These myocytes retain many
characteristics of freshly isolated cells but have distinct
differences. These cells become quiescent after enzymatic
digestion and passaging. Despite an abundant supply of
mitochondria and contractile proteins, the sarcomeres be-
come disrupted during division and do not reestablish their
characteristic functional format. However, the metabolic
response of these cells after ischemia is similar to our
intraoperative findings during cardiac operations.26-28 Fur-
thermore, the cellular concentrations of troponin I, troponin
T, and creatine kinase MB isoform are similar to those seen
in vivo. Although the molecular and biochemical natures of
these cells resemble those of in vivo cardiomyocytes, these
cells undergo a partial phenotypic change, become quies-
cent, and regain their ability to divide. Other investigators
have shown that senescent rat cardiomyocytes might also
regain their ability to divide in culture. Therefore despite
their quiescent state, we believe that these cells are pheno-
typically cardiomyocytes, retain many characteristics of
normal human myocardium, and might simulate the human
heart during cardioplegic arrest.
Limitations and Future Studies
A few limitations of these studies must be acknowledged to
facilitate objective evaluation of these data. First, we do not
provide an assessment of NO production or NO-superoxide
anion balance in the present study. Although these represent
well-known actions of BH4, such measurements would have
strengthened our conclusions. Our data suggest that the
addition of this cofactor reduces oxidative stress and im-
proves NO-mediated vasodilatation to acetylcholine. This is
indirect evidence that BH4 restores the balance between NO
and reactive oxygen species after I/R. Second, other mech-
anisms of I/R injury were not assessed, particularly neutro-
phil activation or reactive oxygen species production. Third,
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we did not measure the circulating levels of BH4. This
remains a challenging assay that is only available at a few
centers in the world; however, the concentrations of BH4
used have been previously demonstrated to result in in-
creased plasma levels in rats. Fourth, it would have been
nice to have confirmatory measurements of lactate dehydro-
genase, creatine kinase, or troponin release from isolated
human cardiomyocytes to support the results of the trypan
blue uptake assay. Finally, the animal studies were con-
ducted after 7 days of treatment with BH4. No data are
available on acute treatment with BH4, except for the in
vitro cell-culture experiments.
Clearly, the most convincing evidence for BH4 as a
mediator of I/R would come from experiments conducted in
the setting of cofactor deficiency. Recently, a BH4-deficient
mouse has been described.12,29 The hyperphenylalaninemic
mouse mutant (hph-1) displays 90% deficiency in guinane
triphosphate cyclohydrolase I, the rate-limiting step in the
synthesis of BH4. We are currently conducting studies to
examine whether global I/R injury is exaggerated in hph-1,
BH4-deficient mice.
Conclusions
Supplemental BH4 exerts a novel cardioprotective effect on
left ventricular function, endothelial-vascular reactivity, ox-
idative damage, and cardiomyocyte injury after I/R and
might represent an important cellular target for future op-
erative myocardial-protection strategies. We suggest that a
relative deficiency of BH4 might occur during I/R, which
might shift the balance between NOS-catalyzed NO produc-
tion and superoxide anion generation; this cellular mecha-
nism is restored with cofactor therapy.
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Discussion
Dr David Follette (Sacramento, Calif). I have had an inter-
est in I/R for more than 25 years. Although cardioprotective
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strategies have been perfected during this period of time, we
only recently have begun to understand the complex molecular
interactions that are involved in I/R injury. Earlier in this
meeting, we heard how cyclosporine and FK-506 provide pro-
tection against I/R by means of calcineurin inhibition. Many of
the contributions that have enhanced our understanding of this
complex topic have been made by Dick Weisel and the Toronto
group. Today’s study, so nicely presented by Dr Verma, con-
tinues this fine tradition.
We now know that the severity of reperfusion injury is related
to the complex interactions between the endothelial cell and the
cardiac myocyte. As has been shown by Dr Verma today, I/R leads
to an imbalance of NO and superoxide generation. This then
results in endothelial cell dysfunction and tissue destruction. It
appears that the cofactor BH4 was shown to modify this reaction.
I have several questions for Dr Verma. How did you select the
7-day pretreatment period in your animals?
Dr Verma. Thank you, Dr Follette, for your kind comments.
The 7-day treatment was based on a previous study in which
treating rats at 25 mgkg1d1 for 7 days results in a 3-fold
increase in the plasma BH4 levels. We used that as an index of
loading. Unfortunately, we did not measure BH4 in this study.
Dr Follette. That then leads into the next question. Can you
give us your thoughts on the mechanism of how exogenous sup-
plementation works?
Dr Verma. BH4 may provide protection from ischemia and
reperfusion by interactions with both the endothelial cell and
cardiomyocyte. In the endothelial cell, BH4 serves as a key reduc-
ing cofactor, facilitating coupling of eNOS into a predominantly
NO (vs superoxide) producing enzyme. This, in turn, results in
improvement in endothelial function, a key component of reper-
fusion injury. Our data also demonstrate that BH4 exerts direct
cardiomyocyte protection, independent of other cell types. This
may be related to augmented cardiomyocyte NO production,
which we have previously demonstrated to be an important medi-
ator of mitochondrial potassium channel opening in human cardi-
omyocytes. Opening of these channels results in intramitochon-
drial depolarization and augmented cellular respiration, with
resultant decreases in intracellular calcium.
Dr Follette. Do you believe then that ischemia causes the BH4
levels to drop acutely?
Dr Verma. Yes, and actually there are other studies in lung
ischemia models that have demonstrated diminished BH4, al-
though not in a cardiac I/R model.
Dr Follette. Is it possible then that BH4 does not have much to
do with reperfusion but rather induces ischemic tolerance?
Dr Verma. Clearly I think the evidence so far in the literature
supports the concept that the greatest damage occurs to the endo-
thelium during the reperfusion phase. We do not have data on BH4,
but if you compare the effects on coronary endothelial function
between ischemia and I/R, clearly the reperfusion component is
much higher than that of the ischemia component in terms of
impairment in acetylcholine responses. I do believe that BH4 is
helping the reperfusion phase. I think we are raising the levels to
a supranormal level, and that reserve is decreasing superoxide and,
through that mechanism, preventing cardiac dysfunction and en-
dothelial dysfunction. It is a hard question to answer in the absence
of NO and superoxide measurements. I think we will have those
measurements in the next few months.
Dr Follette. Perhaps you have already partially answered it
earlier when you stated that when you gave the BH4 acutely it did
not have the same effects as the pretreated, and therefore perhaps
it is inducing some form of tolerance rather than necessarily
affecting the reperfusion process.
Dr Verma. This is possible. The other point is that these are
normal rats. Probably the results would be different or more
dramatic in dysfunctional hearts.
Dr Follette. Lastly, the use of the cardiac myocyte model is
intriguing, and I was especially impressed with your critique of
the method in your article. Can you speculate on how BH4 can
provide direct myocyte protection independent of endothelial
cell function, which we have always assumed was NO’s pri-
mary site of action.
Dr Verma. Recently, we examined the effects of L-arginine
and other agents, NO donors, on cardiomyocytes (independent of
endothelial cells). Agents that increase NO independent of endo-
thelial cells afford protection in the cardiomyocyte model by
opening potassium channels in the mitochondria. That is the mech-
anism that has been proposed. As you know, NO can stimulate
cyclic guanosine monophosphate, which facilitates the opening of
potassium channels.
Dr Michael Mulligan (Seattle, Wash). I have just a couple
of comments. I think that your hypothesis about how this
compound is potentially working is very interesting, but we
have to be careful in interpreting that. I think that your results
are not surprising given the fact that we have seen this already
in the pig heart from the group at Texas A&M back in 1996, but
BH4 is also known to be an oxygen radical scavenger in and of
itself, and therefore it could be having very nonspecific func-
tions as they relate to NO physiology. We have to be careful
whether we think that it is working by stabilizing endothelial
NOS, such that we produce more NO, and that is somehow
protective. Excess NO is toxic to endothelial cells, and in fact,
BH4 has been shown to be protective against NO-induced
endothelial toxicity. It has also been shown in 2 articles that
relate to lung injury (one of them to ischemic lung injury) that
NO is injurious to the lung, and BH4 has also been shown to
potentiate neuronal toxicity in ischemic brain injury.
I think there is more to this story. There might be something
specific about the isoenzyme system in the heart, and it might
rely on a balanced stimulation of endothelin A and B receptors
that relates to NO physiology in ways that we do not under-
stand.
I have been working with NO as it relates to acute lung injury
since 1990, and I still cannot stand up and say it is all good or it
is all bad, and I cannot explain to you how modulation of endo-
thelial NOS activity is so discretely going to result in production of
excessive and injurious peroxynitrite or protective NO.
It is a very elegant study, but I just would advise you from
experience that we have to be careful in the way that we interpret
these things.
Dr Verma. Now, in response to your question about the pig
injury model, no functional data were provided in that study. They
did demonstrate that in the pig heart subjected to I/R, BH4 acutely
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improves endothelial function. I do not know of any cardiac
functional data available except those from this study.
Your question about NO being toxic in terms of function is an
important one, and clearly our group has demonstrated that L-
arginine in higher doses may impair contractility. Probably we
should just be using a cofactor that does not stimulate NO pro-
duction already but restores the balance between NO and super-
oxide. I personally believe that a combination of low doses of
L-arginine and BH4 may work out to be ideal; however, this
hypothesis remains to be tested. However, your comments are very
well taken, and the precarious balance between the actions of NO
on the heart must be kept in mind.
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